[1]Siegel R L, Giaquinto A N, Jemal A. Cancer statistics, 2024[J]. CA: A Cancer Journal for Clinicians, 2024, 74(1): 12 ～ 49.
 [2]Cao W, Chen H-D, Yu Y-W, et al. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chinese Medical Journal, 2021, 134(7): 783 ～ 791.
 [3]Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: Descriptive epidemiology, risk factors, screening, and Prevention[J]. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2014, 23(5): 700 ～ 713.
 [4]Wei S C, Duffy C R, Allison J P. Fundamental mechanisms of immune checkpoint blockade Therapy[J]. Cancer Discovery, 2018, 8(9): 1069 ～ 1086.
 [5]Bagchi S, Yuan R, Engleman E G. Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and Resistance[J]. Annual Review of Pathology, 2021, 16: 223 ～ 249.
 [6]Kang Y-K, Chen L-T, Ryu M-H, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 Trial[J]. The 
Lancet. Oncology, 2022, 23(2): 234 ～ 247.
 [7]Fuchs C S, Doi T, Jang R W, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 Trial[J]. JAMA Oncology, 2018, 4(5): e180013.
 [8]Janjigian Y Y, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 Trial[J]. Lancet (london, England), 2021, 398(10294): 27 ～ 40.
 [9]Wang F, Wei X L, Wang F H, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase ib/II clinical trial NCT02915432[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2019, 30(9): 1479 ～ 1486.
 [10]Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric Adenocarcinoma[J]. Nature, 2014, 513(7517): 202 ～ 209.
 [11]Le D T, Kim T W, Van Cutsem E, et al. Phase II Open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2020, 38(1): 11 ～ 19.
[12]Lei X, Wang Y, Shan F, et al. Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-Positive[J]. Journal of the Chinese Medical Association: JCMA, 2023, 86(8): 717 ～ 724.
 [13]Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 Study[J]. The Lancet. Oncology, 2020, 21(10): 1353 ～ 1365.
 [14]Wang F, Wei X L, Wang F H, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase ib/II clinical trial NCT02915432[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2019, 30(9): 1479 ～ 1486.
 [15]Kim S T, Cristescu R, Bass A J, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric Cancer[J]. Nature Medicine, 2018, 24(9): 1449 ～ 1458.
 [16]Bai Y, Xie T, Wang Z, et al. Efficacy and predictive biomarkers of immunotherapy in Epstein-barr virus-associated gastric Cancer[J]. Journal for ImmunoTherapy of Cancer, 2022, 10(3): e004080.
 [17]Chen Y, Jia K, Sun Y, et al. Predicting response to immunotherapy in gastric cancer via Multi-dimensional analyses of the tumour immune Microenvironment[J]. Nature Communications, 2022, 13(1): 4851.
 [18]Shoji H, Kudo-Saito C, Nagashima K, et al. Myeloid subsets impede the efficacy of Anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR Study)[J]. Journal for ImmunoTherapy of Cancer, 2024, 12(11): e010174.
 [19]Uhlik M, Pointing D, Iyer S, et al. XernaTM TME panel is a machine Learning-based transcriptomic biomarker designed to predict therapeutic response in multiple Cancers[J]. Frontiers in Oncology, 2023, 13: 1158345.
 [20]Janjigian Y Y, Maron S B, Chatila W K, et al. First-line pembrolizumab and trastuzumab in HER2-positive esophagogastric Cancer[J]. The Lancet. Oncology, 2020, 21(6): 821 ～831.
 [21]Circulating tumor DNA as a predictive biomarker for clinical outcomes with margetuximab and pembrolizumab in pretreated HER2-positive gastric/ gastroesophageal adenocarcinoma CancerNetwork[EB/OL]. ([no date])[2025–10–09]. https://www.cancernetwork.com/view/print-circulating-tumor-dna-as-a-predictive-biomarker-forclinical-outcomes-with-margetuximab-and-pembrolizumab-in-pretreated-her2-positive-gastric-gastroesophageal-adenocarcinoma?utm_source=chatgpt.com.
 [22]Zhang J, Wang L, Zhang S, et al. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer Patients[J]. BMC Cancer, 2024, 24(1): 266.
 [23]Munson P V, Adamik J, Hartmann F J, et al. Polyunsaturated fatty Acid-bound α-fetoprotein promotes immune suppression by altering human dendritic cell Metabolism[J]. Cancer Research, 2023, 83(9): 1543 ～ 1557.
 [24]Zhang J, Wang L, Zhang S, et al. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer Patients[J]. BMC Cancer, 2024, 24(1): 266.
 [25]Sun H, Chen L, Huang R, et al. Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint Inhibitors[J]. Frontiers in Nutrition, 2022, 9: 1038118.
 [26]Pan Y, Ma Y, Dai G. The prognostic value of the prognostic nutritional index in patients with advanced or metastatic gastric cancer treated with Immunotherapy[J]. Nutrients, 2023, 15(19): 4290.
 [27]Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment systemic Immune-inflammation index in gastric cancer: A meta-Analysis[J]. Frontiers in Oncology, 2021, 11: 537140.
 [28]Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment systemic Immune-inflammation index in gastric cancer: A meta-Analysis[J]. Frontiers in Oncology, 2021, 11: 537140.
 [29]Gou M, Qu T, Wang Z, et al. Neutrophil-to-lymphocyte ratio (NLR) predicts PD-1 inhibitor survival in patients with metastatic gastric Cancer[J]. Journal of Immunology Research, 2021, 2021: 2549295.
 [30]Gou M, Qu T, Wang Z, et al. Neutrophil-to-lymphocyte ratio (NLR) predicts PD-1 inhibitor survival in patients with metastatic gastric Cancer[J]. Journal of Immunology Research, 2021, 2021: 2549295.
 [31]Tong G, Zhu M, Chen Y, et al. Intratumoral CD8+ T cells as a potential positive predictor of chemoimmunotherapy response in PD-L1-negative advanced gastric cancer patients: A retrospective cohort Study[J]. Journal of Gastrointestinal Oncology, 2022, 13(4): 1668 ～ 1678.
 [32]Choo J, Kua L F, Soe M Y, et al. Clinical relevance of PD-1 positive CD8 T-cells in gastric Cancer[J]. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023, 26(3): 393 ～ 404.
 [33]Davar D, Dzutsev A K, McCulloch J A, et al. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma Patients[J]. Science (new York, N.Y.), 2021, 371(6529): 595 ～ 602.